ShockWave Medical, Inc. revised earnings guidance for the full year 2022. For the year, the company expected revenue to range from $435 million to $455 million up from the previous guidance range of $405 million to $425 million.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
328.9 USD | +0.10% | +0.42% | +72.58% |
Apr. 11 | Health Care Slips on Risk Bias -- Health Care Roundup | DJ |
Apr. 09 | CL King Downgrades ShockWave Medical to Neutral From Buy, Cuts Price Target to $335 From $368 | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+72.58% | 12.32B | |
-18.04% | 7.96B | |
+3.57% | 5.84B | |
+6.65% | 5.11B | |
+20.83% | 4.28B | |
-19.84% | 4B | |
-41.19% | 2.15B | |
+0.25% | 2.01B | |
+4.02% | 1.8B | |
-41.64% | 1.33B |
- Stock Market
- Equities
- SWAV Stock
- News Shockwave Medical, Inc.
- ShockWave Medical, Inc. Revised Earnings Guidance for the Full Year 2022